Home Tags Non-small-cell lung cancer

Tag: non-small-cell lung cancer

Preclinical Data Highlights the Differentiating Properties of MYTX-011

Preclinical data highlighting the differentiating properties of Mythic Therapeutics' investigational cMET-targeting antibody-drug conjugates (ADC), MYTX-011, published in April 30, 2024 edition of Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research (AACR), demonstrated that this novel ADC which leverages Mythic’s innovative FateControl™ technology, actively navigated inside of cells, potentially increasing delivery of anti-cancer agents to tumor cells with less impact on healthy cells.

FDA Grants Fast Track Designation to Rinatabart Sesutecan for Patients with...

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for rinatabart sesutecan (Rina-S; PRO1184), a folate receptor alpha (FRα / FOLR1)...

Phase 2 LUMINOSITY Study Shows Positive Results for Telisotuzumab Vedotin in...

Phase 2 LUMINOSITY Study Shows Positive Results for Telisotuzumab Vedotin in for Patients with Previously Treated Non-Small Cell Lung Cancer

What to Expect at ASCO ’23: Mythic Therapeutics’ MYTX-011 Trial In...

During the annual meeting of the American Society of Clinical Oncology (ASCO) held June 2-6, 2023 in Chicago, Illinois, and online, cancer researchers and...

Daiichi Sankyo and AstraZeneca Sign Collaboration with Lung Cancer Research Foundation;...

The Lung Cancer Research Foundation (LCRF), a leading nonprofit organization focused on funding innovative, high-reward research with the potential to extend survival and improve...

Eisai and Bristol Myers Squibb Sign Global Strategic Collaboration to Jointly...

In a statement released earlier today, Eisai and Bristol-Myers Squibb confirm that the two companies have entered into an exclusive global strategic collaboration agreement...

ESMO 2020: Updated Interim Data of XMT-1536 Supports Continued Development in...

Updated interim phase I date for the safety, tolerability, and efficacy porting for the ovarian cancer cohort of an ongoing expansion study evaluating XMT-1536...

Daiichi Sankyo and AstraZeneca to Jointly Evaluate Patritumab Deruxtecan + Osimertinib...

Earlier this week Daiichi Sankyo and AstraZeneca confirmed that the companies had entered into a clinical trial collaboration with to evaluate the combination of...

Mersana Reports Updated Data from the XMT-1536 Phase I Dose Escalation...

Mersana Therapeutics, a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet...

Clinical Trial with Investigational Potential First-in-class HER3-targeting Antibody-drug Conjugate

A first patient has been dosed in a phase I study evaluating the safety and tolerability of U3-1402, in patients with metastatic or unresectable...

X